An update on anti-Helicobacter pylori treatment in children

Canadian Journal of Gastroenterology

Volumn 19, Issue 7, 2005, Pages 441-445

  Khurana, Renuka ^a   Fischbach, Lori ^b   Chiba, Naoki ^c,e   Veldhuyzen van Zanten, Sander ^d  

^a PARKLAND HEALTH AND HOSPITAL SYSTEM   (United States)

^b UNIVERSITY OF NORTH TEXAS   (United States)

^c Surrey GI Clinic   (Canada)

^d DALHOUSIE UNIVERSITY   (Canada)

^e MCMASTER UNIVERSITY   (Canada)

Author keywords

Children; Helicobacter pylori; Review; Treatment efficacy; Update

Indexed keywords

AMOXICILLIN; BISMUTH; CIMETIDINE; CLARITHROMYCIN; FURAZOLIDONE; HISTAMINE H2 RECEPTOR ANTAGONIST; METRONIDAZOLE; NITROIMIDAZOLE DERIVATIVE; OMEPRAZOLE; PROTON PUMP INHIBITOR; SUCRALFATE; TINIDAZOLE;

ANTIBIOTIC RESISTANCE; ASIA; BRAIN DISEASE; CANADA; CLINICAL TRIAL; CONSENSUS DEVELOPMENT; DATA BASE; DEVELOPED COUNTRY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; ERADICATION THERAPY; EUROPE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INFECTION RATE; INFORMATION PROCESSING; MIDDLE EAST; NONHUMAN; NORTH AMERICA; PRIORITY JOURNAL; REINFECTION; REVIEW; SPAIN;

EID: 23844459842     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2005/289568     Document Type: Review

References (78)

1. Bourke B, Jones N, Sherman F. Helicobacter pylori infection and peptic ulcer disease in children. Pediatr Infect Dis J 1996;15:1-13.
2. Bujanover Y, Reif S, Yahav J. Helicobacter pylori and peptic disease in the pediatric patient. Pediatr Clin North Am 1996;43:213-34.
3. Drumm B. Helicobacter pylori in the pediatric patient. Gastroenterol Clin North Am 1993;22:169-82.
4. Israel DM, Hassall E. Treatment and long-term follow-up of Helicobacter pylori-associated duodenal ulcer disease in children. J Pediatr 1993;123:53-8.
5. Sherman P, Hassall E, Hunt RH, Fallone CA, Veldhuyzen van Zanten S, Thompson AB. Canadian Helicobacter Study Group consensus conference on the approach to Helicobacter pylori infection in children and adolescents. Can J Gastroenterol 1999;13:553-9.
6. Gold BD, Colletti RB, Abbott M, et al; North American Society for Pediatric Gastroenterology and Nutrition. Helicobacter pylori infection in children: Recommendations for diagnosis and treatment. J Pediatr Gastroenterol Nutr 2000;31:490-7.
7. Malfertheiner P, Megraud F, O'Morain C, et al; European Helicobacter pylori Study Group. Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002;16:167-80.
8. Hunt RH, Fallone C, Veldhuyzen van Zanten SJO, Sherman P, Smaill F, Thomson AB; Canadian Helicobacter Study Group. Risks and benefits of Helicobacter pylori eradication: Current status. Can J Gastroenterol 2002;16:57-62.
9. Yeung CK, Fu KH, Yuen KY, et al. Helicobacter pylori and associated duodenal ulcer. Arch Dis Child 1990;65:1212-6.
10. Oderda G, Caristo F, Kuvidi M, et al. Evaluation of different treatment schedules in childhood Helicobacter pylori gastritis: A 10 year experience. Gut 1999;45 (Suppl 111):A94. (Abst)
11. Choe YH, Kim SK, Son BK, Lee DH, Hong YC, Pai SH. Randomized placebo controlled trial of Helicobacter pylori eradication for iron-deficiency anemia in preadolescent children and adolescents. Helicobacter 1999;4:135-9.
12. Huang FC, Chang MH, Hsu HY, Lee PI, Shun CT. Long-term follow-up of duodenal ulcer in children before and after eradication of Helicobacter pylori. J Pediatr Gastroenterol Nutr 1999;28:76-80.
13. Sherman P, Shames B, Loo V, Marlow A, Drumm B, Penner J. Omeprazole therapy for Helicobacter pylori infection. Scand J Gastroenterol 1992;27:1018-22.
14. Fischbach LA, Goodman KJ, Feldman M, Aragaki C. Sources of variation of Helicobacter pylori treatment success in adults worldwide: A meta-analysis. Int J Epidemiol 2002;31:128-39.
15. Radhakrishnan S, al Nakih B, Kalaoui M, Patric J. Helicobacter pylori-associated gastritis in Kuwait: Endoscopy-based study in symptomatic and asymptomatic children. J Pediatr Gastroenterol Nutr 1993;16:126-9.
16. Gottrand F, Kalach N, Spyckerelle C, et al. Omeprazole combined with amoxicillin and clarithromycin in the eradication of Helicobacter pylori in children with gastritis: A prospective randomized double-blind trial. J Pediatr 2001;139:664-8.
17. Kato S, Takeyama J, Ebina K, Naganuma H. Omeprazole-based dual and triple regimens for Helicobacter pylori eradication in children. Pediatrics 1997;100:E3.
18. Behrens R, Lang T, Keller KM, et al. Dual versus triple therapy of Helicobacter pylori infection: Results of multicentre trial. Arch Dis Child 1999;81:68-70.
19. Alarcon T, Martinez MJ, Domingo D, et al. Eradication rates on dual or triple therapies including amoxicillin according to the amoxicillin MIC level in a pediatric population. Gut 1999;45:A99. (Abst)
20. Shashidhar H, Peters J, Lin CH, Rabah R, Thomas R, Tolia V. A prospective trial of lansoprazole therapy for pediatric Helicobacter pylori infection. J Pediatr Gastroenterol Nutr 2000;30:276-82.
21. Dohil R, Israel DM, Hassall E. Effective 2-wk therapy for Helicobacter pylori disease in children. Am J Gastroenterol 1997;92:244-7.
22. 2 receptor antagonist or omeprazole in the eradication of Helicobacter pylori in children with duodenal ulcer. Gut 1998;43(Suppl 2):A74. (Abst)
23. Chan KL, Zhou H, Ng DK, Tam PK. A prospective study of a one-week nonbismuth quadruple therapy for childhood Helicobacter pylori infection. J Pediatr Surg 2001;36:1008-11.
24. De Giacomo C, Fiocca R, Villani R, et al. Helicobacter pylori infection and chronic gastritis: Clinical, serological and histological correlations in children treated with amoxicillin and colloidal bismuth subcitrate. J Pediatr Gastroenterol Nutr 1990;11:310-6.
25. Mahony MJ, Wyatt JI, Littlewood JM. Management and response to treatment of Helicobacter pylori gastritis. Arch Dis Child 1992;67:940-3.
26. McNulty CA. The treatment of Campylobacter-associated gastritis. Am J Gastroenterol 1987;82:245-7.
27. Goddard AF, Sherwood PV. Bioavailability of antimicrobials after oral and parenteral administration. In: Hunt RH, Tytgat GNJ, eds. Helicobacter pylori: Basic Mechanisms to Clinical Cure. Dordrecht: Kluwer Academic Publishers, 1998:392-7.
28. Kalach N, Raymond J, Benhamou PH, et al. Spiramycin as an alternative to amoxicillin treatment associated with lansoprazole/metronidazole for Helicobacter pylori infection in children. Eur J Pediatr 1998;157:607-8.
29. Kalach N, Raymond J, Benhamou PH, Bergeret M, Dupont C. Short-term treatment with amoxycillin, clarithromycin and lansoprazole during Helicobacter pylori infection in children. Clin Microbiol Infect 1999;5:235-6.
30. Raymond J, Kalach N, Bergeret M, et al. Effect of metronidazole resistance on bacterial eradication of Helicobacter pylori in infected children. Antimicrob Agents Chemother 1998;42:1334-5.
31. Lopez-Brea M, Martinez MJ, Domingo D, Sanchez I, Alarcon T. Metronidazole resistance and virulence factors in Helicobacter pylori as markers for treatment failure in a paediatric population. FEMS Immunol Med Microbiol 1999;24:183-8.
32. Glupczynski Y, Burette A, De Koster E, et al. Metronidazole resistance in Helicobacter pylori. Lancet 1990;335:976-7.
33. Dhaenens L, Szczebara F, Husson MO. In-vitro activities of clarithromycin and other antimicrobial agents against Helicobacter pylori isolated from children. J Antimicrob Chemother 1996;38:318-9.
34. Bak-Romaniszyn L, Planeta-Malecka I, Czkwianianc E, Rozynek E, Dzierzanowska D, Laszewicz W. [Drug sensitivity of Helicobacter pylori strains in children and young people from the region of Lodz]. Med Wieku Rozwoj 2003;7:129-35.
35. Kalach N, Benhamou PH, Bergeret M, et al. [Acquisition of secondary resistance after a first course failure of treatment of Helicobacter pylori infection in children]. Arch Pediatr 2002; 9:130-5.
36. Crone J, Granditsch G, Huber WD, et al. Helicobacter pylori in children and adolescents: Increase of primary clarithromycin resistance, 1997-2000. J Pediatr Gastroenterol Nutr 2003; 36:368-71.
37. Street M, Caruana P, Caffarelli C, et al. Antibiotic resistance and antibiotic sensitivity based treatment in Helicobacter pylori infection: Advantages and outcome. Arch Dis Child 2001;84:419-22.
38. Rozynek E, Dzierzanowska D, Celinska-Cedro D, Jeljaszewicz J. Primary resistance to metronidazole and other antibiotics of Helicobacter pylori isolated from children in Poland. Eur J Clin Microbiol Infect Dis 1997;16:943-4.
39. Lopez-Brea M, Martinez MJ, Domingo D, Alarcon T. A 9-year study of clarithromycin and metronidazole resistance in Helicobacter pylori from Spanish children. J Antimicrob Chemother 2001;48:295-7.
40. Kalach N, Bergeret M, Benhamou PH, Dupont C, Raymond J. High levels of resistance to metronidazole and clarithromycin in Helicobacter pylori strains in children. J Clin Microbiol 2001;39:394-7.
41. Cabrita J, Oleastro M, Matos R, et al. Features and trends in Helicobacter pylori antibiotic resistance in Lisbon area, Portugal (1990-1999). J Antimicrob Chem 2000;46:1029-31.
42. Bontems P, Devaster J, Corvaglia L, et al. Twelve year observation of primary and secondary antibiotic-resistant Helicobacter pylori strains in children. Pediatr Infect Dis J 2001;20:1033-8.
43. Mentis AF, Roma E, Pangalis A, Katsiyiannakis E. Susceptibilities of Helicobacter pylori strains isolated from children with gastritis to selected antibiotics. J Antimicrob Chemother 1999;44:720-2.
44. Rerksuppaphol S, Hardikar W, Midolo PD, Ward P. Antimicrobial resistance in Helicobacter pylori isolates from children. J Paediatr Child Health 2003;39:332-5.
45. Fujimura S, Kato S, Kawamura T, Watanabe A. In vitro activity of rifampin against Helicobacter pylori isolated from children and adults. J Antimicrob Chemother 2002;49:541-3.
46. Kato S, Fujimura S, Udagawa H, et al. Antibiotic resistance of Helicobacter pylori strains in Japanese children. J Clin Microbiol 2002;40:649-53.
47. Yang YJ, Yang JC, Jeng YM, Chang MH, Ni YH. Prevalence and rapid identification of clarithromycin-resistant Helicobacter pylori isolates in children. Pediatr Infec Dis J 2001;20:662-6.
48. Tolia V, Brown W, El-Baba M, Lin CH. Helicobacter pylori culture and antimicrobial susceptibilities from pediatric patients in Michigan. Pediatr Infect Dis J 2000;19:1167-71.
49. Torres J, Camorlinga-Ponce M, Perez-Perez G, et al. Increasing multidrug resistance in Helicobacter pylori strains isolated from children and adults in Mexico. J Clin Microbiol 2001;39:2677-80.
50. Domingo D, Alarcon T, Vega AE, Garcia JA, Martinez MJ, Lopez-Brea M. [Microbiological factors that influence the eradication of Helicobacter pylori in adults and children]. Enferm Infecc Microbiol Clin 2002;20:431-4.
51. Jesch I, Kindermann A, Krauss-Etschmann S, et al. Prevalence of clarithromycin-resistant H. pylori strains in children: Effect on therapy. Gut 1999;45:A93. (Abst)
52. Kalach N, Benhamou PH, Campeotto F, Bergeret M, Dupont C, Raymond J. Clarithromycin resistance and eradication of Helicobacter pylori in children. Antimicrob Agents Chemother 2001;45:2134-5.
53. Kalach N, Benhamou PH, Dupout C, et al. Helicobacter pylori in children: Acquisition of antimicrobial resistance after an initial course of treatment. J Clin Microbiol 2001;39:3018-9.
54. Feydt-Schmidt A, Russmann H, Lehn N, et al. Fluorescence in situ hybridization vs epsilometer test for detection of clarithromycin-susceptible and clarithromycin-resistant Helicobacter pylori strains in gastric biopsies from children. Aliment Pharmacol Ther 2002;16:2073-9.
55. Dzierzanowska-Fangrat K, Rozynek E, Jozwiak P, Celinska-Cedro D, Madalinski K, Dzierzanowska D. Primary resistance to clarithromycin in clinical strains of Helicobacter pylori isolated from children in Poland. Int J Antimicrob Agents 2001;18:387-90.
56. Cucchiara S, Salvia G, Az-Zeqeh N, et al. Helicobacter pylori gastritis and non-ulcer dyspepsia in childhood. Efficacy of one-week triple antimicrobial therapy in eradicating the organism. Ital J Gastroenterol 1996;28:430-5.
57. Cilleruelo ML, Urruzuno P, Martinez NJ, et al. Helicobacter pylori reinfection after eradication in children. Gut 1997;41:A70. (Abst)
58. Martinez MJ, Sanz JC, Garcia N, et al. Reinfection after Helicobacter pylori eradication in pediatric patients. Gut 1999;45:A96. (Abst)
59. Walsh D, Goggin N, Rowland M, Durnin M, Moriarty S, Drumm B. One week treatment for Helicobacter pylori infection. Arch Dis Child 1997;76:352-5.
60. Oderda G, Vaira D, Ainley C, et al. Eighteen month follow up of Helicobacter pylori positive children treated with amoxicillin and tinidazole. Gut 1992;33:1328-30.
61. Kato S, Abukawa D, Furuyama N, Iinuma K. Helicobacter pylori reinfection rates in children after eradication therapy. J Pediatr Gastroenterol Nutr 1998;27:543-6.
62. Xia HX, Talley NJ, Keane CT, O'Morain CA. Recurrence of Helicobacter pylori after successful eradication: Nature and possible causes. Dig Dis Sci 1997;42:1821-34.
63. Moshkowitz M, Reif S, Brill S, et al. One-week triple therapy with omeprazole, clarithromycin, and nitroimidazole for Helicobacter pylori infection in children and adolescents. Pediatrics 1998; 102:E14.
64. Kawakami E, Ogata SK, Portorreal AC, Magni AM, Pardo ML, Patricio FR. Triple therapy with clarithromycin, amoxicillin and omeprazole for Helicobacter pylori eradication in children and adolescents. Arq Gastroenterol 2001;38:203-6.
65. Yanez P, la Garza AM, Perez-Perez G, Cabrera L, Munoz O, Torres J. Comparison of invasive and noninvasive methods for the diagnosis and evaluation of eradication of Helicobacter pylori infection in children. Arch Med Res 2000;31:415-21.
66. Cammarota G, Cianci R, Cannizzato O, et al. Efficacy to two one-week rabreprazole/levofloxacin-based triple therapies for Helicobacter pylori infection. Aliment Pharamacol Ther 2000;14:1339-43.
67. Di Caro S, Assunta Zocco M, Cremonini F, et al. Levofloxacin based regimens for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 2002;14:1309-12.
68. Di Caro S, Ojetti V, Zocco MA, et al. Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication. Aliment Pharmacol Ther 2002;16:527-32.
69. Nagahara A, Miwa H, Yamada T, Kurosawa A, Ohkura R, Sato N. Five-day proton pump inhibitor-based quadruple therapy regimen is more effective than 7-day triple therapy regimen for Helicobacter pylori infection. Aliment Pharmacol Ther 2001;15:417-21.
70. Nagahara A, Miwa H, Ogawa K, et al. Addition of metronidazole to rabeprazole-amoxicillin-clarithromycin regimen for Helicobacter pylori infection provides an excellent cure rate with five-day therapy. Helicobacter 2000;5:88-93.
71. Treiber G, Ammon S, Schneider E, Klotz U. Amoxicillin/metronidazole/omeprazole/clarithromycin: A new, short quadruple therapy for Helicobacter pylori eradication. Helicobacter 1998;3:54-8.
72. Neville PM, Everett S, Langworthy H, et al. The optimal antibiotic combination in a 5-day Helicobacter pylori eradication regimen. Aliment Pharmacol Ther 1999;13:497-501.
73. Smith DM, Straffon LH. Dental staining due to tetracycline administration. Mich Med 1967;66:464-6.
74. Scopp IW, Kazandjian G. Tetracycline-induced staining of teeth. Postgrad Med 1986;79:202-3.
75. Clark I, Whitten R, Molyneux M, Taylor T. Salicylates, nitric oxide, malaria, and Reye's syndrome. Lancet 2001;357:625-7.
76. Perri F, Festa V, Clemente R, et al. Randomized study of two "rescue" therapies for Helicobacter pylori-infected patients after failure of standard triple therapies. Am J Gastroenterol 2001;96:58-62.
77. Wong WM, Gu Q, Lam SK, et al. Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs quadruple therapy as second-line treatment for Helicobacter pylori infection. Aliment Pharmacol Ther 2003;17:553-60.
78. Nista EC, Candelli M, Cremonini F, et al. Levofloxacin-based triple therapy vs quadruple therapy in second-line Helicobacter pylori treatment: A randomized trial. Aliment Pharmacol Ther 2003; 18:627-33.